title: Carbon-11 choline or FDG-PET for staging of oesophageal cancer?
abstract: We investigated the feasibility of using carbon-11 choline (CHOL) positron emission tomography (PET) for the staging of oesophageal cancer, in comparison with fluorine-18 fluorodeoxyglucose (FDG) PET, using histopathological findings as the gold standard. Eighteen patients were studied: 16 patients with cancer of the oesophagus or gastro-oesophageal junction and two with in situ carcinoma/high-grade dysplasia. PET imaging was performed 5 min (CHOL) or 90 min (FDG) after injection of 370 MBq of the tracer. PET images were analysed by two independent and blinded physicians using visual and standardised uptake value (SUV) analysis. PET results were compared with surgical and histopathological findings. FDG-PET was able to detect all (100%) of the 16 malignant primary lesions, while CHOL-PET detected 73%. In situ carcinoma ( n=1) and high-grade dysplasia ( n=1) were not visualised with either tracer. Diffuse uptake of the tracers was noted in areas of Barrett's oesophagitis. Twelve patients had locoregional metastases (N1) that were not detected with either FDG or CHOL. Six patients had additional distant nodal (M1a) metastases; four of six (66%) were visualised by FDG, and three of five (60%) by CHOL-PET. On a lesion basis, FDG-PET detected 10/12 non-regional metastases (sensitivity 83%), while CHOL-PET detected 5/12 (sensitivity 42%). Haematogenous distant metastases (M1b) were positive on FDG-PET in three of four patients, and on CHOL-PET in two of four. SUV values were significantly higher for FDG (FDG 6.6+/-3.5, CHOL 5.5+/-2.5, P=0.04). CHOL-PET is able to visualise oesophageal carcinoma and its metastases, but appears to be inferior to FDG-PET. Presumably this is the result of lower tumoural uptake and considerable non-specific uptake of CHOL in liver, stomach wall, pancreas and small intestine. Further studies are needed to confirm these data.
authors.affiliation: PET Centre, Groningen University Hospital, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. p.l.jager@nucl.azg.nl
authors.forename: P L
authors.initials: PL
authors.lastname: Jager
authors.forename: T H
authors.initials: TH
authors.lastname: Que
authors.forename: W
authors.initials: W
authors.lastname: Vaalburg
authors.forename: J
authors.initials: J
authors.lastname: Pruim
authors.forename: P
authors.initials: P
authors.lastname: Elsinga
authors.forename: J T
authors.initials: JT
authors.lastname: Plukker
mesh_terms: D002250:Carbon Radioisotopes; D002794:Choline; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging*; D005240:Feasibility Studies; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D013997:Time Factors; D014055:Tomography, Emission-Computed
chemical_list: D002250:Carbon Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D002794:Choline